Showing 2974 results
-
Press release /
-
Ad hoc release /Ad hoc announcement pursuant to Art. 53 LR Mid-term sales guidance rolled forward to +5-6% cc CAGR for 2025-2030, following upgrade of 2024-2029 guidance to +6% cc1Peak sales guidance upgraded for…
-
Press release /Expansion represents significant investment in North Carolina and is expected to create 700 new jobs in the state by end of 2030Enables manufacturing of medicines across company’s main therapeutic…
-
Press release /NEPTUNUS-1 and NEPTUNUS-2 achieved primary objective of reduced disease activity and provided clinically meaningful benefit1 Data showed consistent improvements across secondary…
-
Ad hoc release /Ad hoc announcement pursuant to Art. 53 LRSecond quarterNet sales grew +1% (cc1, +3% USD), with core operating income1 flat (cc and USD)Sales growth driven by priority brands including Kisqali (+43%…
-
Press release /Growing improvement in major molecular response (MMR) rates demonstrated with Scemblix vs. all standard-of-care TKIs including imatinib and second generation (2G) TKIs1 Clinically relevant 15.2%…
-
Press release /Carlsbad location is company’s third US-based radioligand therapy (RLT) manufacturing site New site expands manufacturing footprint to meet future demand; ensures continued on-time delivery rate of…
-
Press release /
Novartis to highlight Rhapsido® data across multiple immune-mediated diseases at EAACI Congress 2026
Results from Rhapsido (remibrutinib) pivotal Phase III RemIND trial, the largest study in chronic inducible urticaria, to be highlighted in late-breaker oral presentationNew Phase IIIb REMIXED… -
Press release /Improved radiographic progression-free survival (rPFS) regardless of disease volume or metastatic presentation achieved with Pluvicto plus standard of care (ARPI + ADT) in PSMAdditionConsistent…
-
Press release /If approved, Itvisma (intrathecal onasemnogene abeparvovec) will be first and only gene replacement therapy for children two years and older, teens and adults with SMA in the European UnionItvisma…